<DOC>
	<DOCNO>NCT02671318</DOCNO>
	<brief_summary>Cytomegalovirus important opportunistic infection kidney transplant , increased mortality , morbidity high cost transplantation . Despite favorable efficacy ( low acute rejection ) result worldwide used regime , tacrolimus , mycophenolate prednisone , investigator local common regimen , tacrolimus , azathioprine prednisone , combination associate high incidence cytomegalovirus infection , disease recurrence . Namely , sirolimus use associate decreased risk cytomegalovirus infection/disease , prospective cohort evaluate conversion sirolimus efficacy decrease cytomegalovirus infection recurrence . Given , investigator propose study initiative attends local need : evaluate conversion sirolimus efficacy decrease cytomegalovirus recurrence kidney transplant .</brief_summary>
	<brief_title>Conversion Sirolimus : Effects Cytomegalovirus Infection Recurrence</brief_title>
	<detailed_description>This protocol prospective , randomize , single center , design evaluate incidence cytomegalovirus recurrence infection/disease two immunosuppressive regimen , first episode cytomegalovirus : ( 1 ) conversion azathioprine mycophenolate sirolimus , regimen wih low dos tacrolimus prednisone ; ( 2 ) Maintenance current regimen first episode cytomegalovirus infection ( azathioprine mycophenolate , combination tacrolimus prednisone ) . Our hypothesis conversion azathioprine sodium mycophenolate sirolimus , low dos tacrolimus , prednisone result low recurrence cytomegalovirus infection/disease kidney transplant recipient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Adult kidney transplant recipient &gt; 18 y.o . Kidney Transplant recipient , first episode cytomegalovirus infection , use current immunosuppressive regimen : azathioprine mycophenolate , tacrolimus prednisone . Retransplant ; Patients panel reactive antibody ( PRA ) equal 50 % , class I class II ; Acute rejection episode last 30 day , episode &gt; 2A Banff criterion ; GFR ( MDRD ) &lt; 40 ml/min ; Proteinuria &gt; 0,5 g/l ; Hemoglobin &lt; 10 g/l and/or leucocytes &lt; 4000 cels/mm3 and/or platelet &lt; 150.000 cels/mm3 ; Triglycerides &gt; 500 mg/dl without use fibrate ; Cholesterol total &gt; 300 mg/dl without use statin ; Hepatic abnormality ; Significant periphery edema ; Pulmonary abnormality breast xray abnormality ; Hyper sensibility sirolimus formula ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cytomegalovirus</keyword>
	<keyword>sirolimus</keyword>
	<keyword>cytomegalovirus recurrence</keyword>
	<keyword>kidney transplant</keyword>
	<keyword>conversion</keyword>
</DOC>